Abion signs iADC platform joint research, licensing deal with LigaChem Biosciences

Bitget2026/09/30 08:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Abion entered a joint research and licensing deal with LigaChem Biosciences to co-develop an iADC drug candidate.
The program combines Abion’s IFN-β mutein immunocytokine-antibody with LigaChem’s proprietary ADC platform for global development and commercialization.
LigaChem secured exclusive rights. It can designate up to five targets under the agreement, effective immediately.
Economics include an upfront payment, research funding, target-based milestones, and sales royalties. Financial terms were not disclosed.
The contract was signed on Sept. 30, 2026. Duration runs through the end of royalty payments for the last product.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abion Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930900696), on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Abion signs iADC platform joint research, licensing deal with LigaChem Biosciences

You may also like

Crypto prices